Taiwan's Biomedical Breakthrough
Sangtech Lab /Safetran Inc. and Taiwan Textile Research Institute Win Silver at 2026 Edison Awards for CellNet Leukocyte Reduction Filter
April 17, 2026 | Safetran Editorial Team
The 2026 Edison Awards — one of the world’s most prestigious innovation competitions — has announced its winners. Taiwan’s groundbreaking medical device technology, the CellNet Leukocyte Reduction Filter, has earned the Silver Award in Energy & Climate Resiliency, recognized for its exceptional cell separation efficiency and high biosafety standards. This milestone marks a landmark achievement for Taiwan’s R&D community on the global medical stage, and signals a transformative leap forward in sustainable blood processing technology.
The Innovation Behind CellNet: Supercritical Fluid (SCF) Processing Technology
At the heart of CellNet’s award-winning design is Supercritical Fluid (SCF) processing technology, a solvent-free, waterless method that hydrophilizes filter media through physical infusion alone. This eliminates the need for chemical solvents, enabling highly efficient leukocyte removal from blood while fully aligning with ESG sustainability and low-carbon manufacturing standards.
Blood filtration devices have long been considered high-pollution medical waste. The CellNet development team reimagined this paradigm through advanced materials engineering, achieving:
- Rapid filtration speed
- High red blood cell (RBC) recovery rates
- High white blood cell (WBC) reduction rates
- Minimal blood component loss
- Zero wastewater, zero pollution — an environmentally friendly production model powered by proprietary biomedical surface modification technology
Performance Advantages: Exceeding International Standards
CellNet’s competitive edge lies in performance metrics that surpass existing global benchmarks:
- Process Innovation: Sangtech’s SCF technology fully preserves material properties, ensuring consistent product quality while meeting ESG targets.
- Superior Filtration Efficiency: Removes up to 83% of blood microparticles, enabling smoother filtration and significantly improving blood storage quality.
- Enhanced Transfusion Safety: CellNet®-filtered blood products reduce potassium buildup by 25% during storage compared to conventional filters, lowering hyperkalemia risk in transfusion patients.
About the Edison Awards: The Hallmark of Realized Innovation
Founded in 1987, the Edison Awards honor proven innovation, outstanding product design, breakthrough services, and visionary leadership in the legacy of Thomas Edison. Judging criteria span four rigorous dimensions: Concept, Value, Delivery, and Impact.
CellNet’s Silver Award, earned in direct competition with the world’s top innovators, confirms that its technology has reached the highest tier of global excellence.
Looking Ahead: From Taiwan to the Global Healthcare Market
With the 2026 Edison Award as validation, CellNet will continue pursuing regulatory approvals and market expansion across Europe and North America. This Silver Award is a commitment, marking Safetran and Sangtech’s dedication to advancing patient safety and transforming blood care worldwide.
About Safetran BioMedical/ Sangtech Lab.
Safetran BioMedical and Sangtech Lab are dedicated to advancing the blood technology industry through expertise in transfusion safety and regenerative medicine. Driven by three core principles — Quality, Safety, and Economic Value — the companies continuously innovate to deliver products that benefit healthcare providers, patients, and the broader medical industry alike.
Keywords:
CellNet leukocyte reduction filter, Edison Awards 2026, Taiwan medical device innovation, supercritical fluid processing, blood filtration technology, transfusion safety, ESG medical manufacturing, SynCore Syntech, Taiwan biomedical, white blood cell filter